Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study

Objective This study aimed to explore possible associations between molecular subtypes and site of distant metastasis in advanced breast cancer (ABC). Methods 3577 ABC patients were selected from 21 hospitals of seven geographic regions in China from 2012-2014. A questionnaire was designed to collect medical information regarding demographic characteristics, risk factors, molecular subtype, recurrence/metastasis information, and disease-free survival (DFS). The cancers were classified into Luminal A, Luminal B, HER2-enriched and Triple Negative subtypes. Chi-square test and multivariate Cox proportional hazard models were performed to explore the associations between molecular subtypes and distant metastasis sites. Results A total of 2393 cases with molecular subtypes information were finally examined. Patients with Luminal A (51.1%) and Luminal B (44.7%) were most prone to bone metastasis, whereas liver metastasis was more frequently observed in HER2-enriched ABC patients (29.1%).The cumulative recurrence and metastasis rates of ABC patients at 36 months of DFS were the most significant within molecular types, of which Triple Negative was the highest (82.7%), while that of Luminal A was the lowest (58.4%). In the adjusted Cox regression analysis, Luminal B, HER2-enriched and Triple Negative subtypes increased the risk of visceral metastasis by 23%, 46% and 87% respectively. In addition, Triple Negative patients had a higher probability of brain metastasis (HR 3.07, 95% CI: 1.04-9.07). Conclusion Molecular subtypes can predict the preferential sites of distant metastasis, emphasizing that these associations were of great help in choices for surveillance, developing appropriate screening and cancer management strategies for follow-up and personalized therapy in ABC patients.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[3]  R. Gelber,et al.  Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jing Peng,et al.  Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics , 2017, Cancer management and research.

[5]  Sung-Bae Kim,et al.  Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[6]  Shuiping Gao,et al.  Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis , 2017, Scientific Reports.

[7]  Xing Li,et al.  miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer , 2017, Breast Cancer Research.

[8]  C. Perou,et al.  Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. , 2017, Cancer research.

[9]  David Cameron,et al.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial , 2017, The Lancet.

[10]  I. Vendrell,et al.  Bone metastasis risk factors in breast cancer , 2017, Ecancermedicalscience.

[11]  B. Ács,et al.  Breast carcinoma subtypes show different patterns of metastatic behavior , 2017, Virchows Archiv.

[12]  J. Watanabe,et al.  Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up , 2017, Breast Cancer Research and Treatment.

[13]  Mounia Elidrissi Errahhali,et al.  First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases , 2017, BMC Women's Health.

[14]  K. Sultanem,et al.  Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype , 2016, Cureus.

[15]  I. Ellis,et al.  Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing? , 2016, Histopathology.

[16]  L. Miller,et al.  EGFR and HER2 signaling in breast cancer brain metastasis. , 2016, Frontiers in bioscience.

[17]  Gary J Whitman,et al.  Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy , 2015, Cancer.

[18]  L. Qian,et al.  Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer. , 2015, International journal of clinical and experimental pathology.

[19]  H. Lee,et al.  Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis , 2015, Oncology.

[20]  U. Schick,et al.  Breast cancer brain metastases - A 12 year review of treatment outcomes. , 2015, Breast.

[21]  A. Paterson,et al.  The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer , 2015, BMC Cancer.

[22]  C. Friedenreich,et al.  The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer , 2015, BMC Cancer.

[23]  B. Calys-Tagoe,et al.  A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana , 2015, BMC Clinical Pathology.

[24]  Z. Ren,et al.  Breast cancer subtypes predispose the site of distant metastases. , 2015, American journal of clinical pathology.

[25]  C. D. Savci-Heijink,et al.  Retrospective analysis of metastatic behaviour of breast cancer subtypes , 2015, Breast Cancer Research and Treatment.

[26]  M. Fernö,et al.  Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Zhenbo Hou,et al.  Profiling of alternative polyadenylation sites in luminal B breast cancer using the SAPAS method , 2014, International journal of molecular medicine.

[28]  B. Cardazzo,et al.  Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer , 2014, BMC Veterinary Research.

[29]  R. Scolyer,et al.  Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma , 2014, British Journal of Cancer.

[30]  M. Martínez-García,et al.  Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline , 2013, Clinical and Translational Oncology.

[31]  B. Ochietti,et al.  Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. , 2013, American journal of cancer research.

[32]  R. Bernards,et al.  A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences , 2013, Molecular oncology.

[33]  Y. Qiao,et al.  The Diverse Distribution of Risk Factors between Breast Cancer Subtypes of ER, PR and HER2: A 10-Year Retrospective Multi-Center Study in China , 2013, PloS one.

[34]  A. Redig,et al.  Breast cancer as a systemic disease: a view of metastasis , 2013, Journal of internal medicine.

[35]  K. Hunt,et al.  Comparison of clinicopathologic features and survival in young American women aged 18–39 years in different ethnic groups with breast cancer , 2013, British Journal of Cancer.

[36]  B. Park,et al.  Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women , 2013, PloS one.

[37]  N. Harbeck,et al.  St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion , 2013, Breast Care.

[38]  L. Miele,et al.  Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. , 2013, American journal of cancer research.

[39]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[40]  M. Campone,et al.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. , 2013, The Lancet. Oncology.

[41]  E. Winer,et al.  Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.

[42]  G. Hortobagyi,et al.  Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer , 2012, Cancer.

[43]  S. Baldus,et al.  Down-Regulation of CDH1 Is Associated with Expression of SNAI1 in Colorectal Adenomas , 2012, PloS one.

[44]  C. Hudis,et al.  Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer , 2012, The breast journal.

[45]  P. Brown,et al.  Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. , 2012, International journal of radiation oncology, biology, physics.

[46]  H. Park,et al.  Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. , 2012, Breast.

[47]  Abid Ahmad Sofi,et al.  Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[48]  Thomas Hielscher,et al.  Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine , 2011, Clinical Cancer Research.

[49]  K. Pogoda,et al.  Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes , 2011, Journal of Neuro-Oncology.

[50]  G. Hortobagyi,et al.  Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Dong-mei Li,et al.  Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets , 2011, Breast Cancer Research and Treatment.

[52]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  W. Jones,et al.  Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy , 2010 .

[54]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[55]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[56]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[57]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[58]  Paula D. Bos,et al.  Mediators of vascular remodelling co-opted for sequential steps in lung metastasis , 2007, Nature.

[59]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[60]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[61]  J. Cedarbaum.  Survival , 2004 .

[62]  M. Oursler,et al.  Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis , 1996, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[63]  R. Foster,et al.  Breast self‐examination practices and breast cancer survival , 1984, Cancer.

[64]  G. Hortobagyi,et al.  The natural history of breast cancer patients with brain metastases , 1979, Cancer.